{"id":"folfirinox-or-gemcitabine-nab-paclitaxel","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"30-70","effect":"Anemia"},{"rate":"20-50","effect":"Thrombocytopenia"},{"rate":"50-80","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"30-60","effect":"Peripheral neuropathy"},{"rate":"50-80","effect":"Fatigue"},{"rate":"20-40","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL4303645","moleculeType":"Small molecule","molecularWeight":"389.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRINOX combines 5-fluorouracil (DNA synthesis inhibitor), leucovorin (5-FU potentiator), irinotecan (topoisomerase I inhibitor), and oxaliplatin (platinum alkylating agent) to attack cancer cells via complementary pathways. Gemcitabine-nab-paclitaxel combines gemcitabine (nucleoside analog inhibiting DNA synthesis) with nab-paclitaxel (albumin-bound paclitaxel that stabilizes microtubules), allowing higher drug delivery to tumors.","oneSentence":"FOLFIRINOX and gemcitabine-nab-paclitaxel are combination chemotherapy regimens that kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and microtubule disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:10.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer (FOLFIRINOX)"},{"name":"Metastatic pancreatic cancer (gemcitabine-nab-paclitaxel)"},{"name":"Locally advanced pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07191418","phase":"NA","title":"Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Roberto Valente","startDate":"2026-03","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":178},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07407231","phase":"NA","title":"Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-09-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":18},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT07226154","phase":"","title":"Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT05630183","phase":"PHASE2","title":"A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2023-03-27","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":81},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT05482893","phase":"PHASE1, PHASE2","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2023-03-15","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)","enrollment":258},{"nctId":"NCT07043270","phase":"PHASE2","title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-09-29","conditions":"Pancreas Adenocarcinoma","enrollment":35},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT05585320","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immuneering Corporation","startDate":"2022-10-31","conditions":"Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)","enrollment":209},{"nctId":"NCT03724994","phase":"","title":"Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer","status":"COMPLETED","sponsor":"Lund University","startDate":"2018-10-30","conditions":"Periampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer","enrollment":201},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT02979483","phase":"NA","title":"Management of Symptomatic Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2016-12-19","conditions":"Pancreas, Management Supportive Care Program","enrollment":110},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT04276857","phase":"NA","title":"Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-05-01","conditions":"Locally Advanced Pancreatic Cancer, Irreversible Electroporation","enrollment":27},{"nctId":"NCT01834235","phase":"PHASE1, PHASE2","title":"QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Precision Biologics, Inc","startDate":"2013-04","conditions":"Pancreatic Cancer, Adult","enrollment":81},{"nctId":"NCT06278454","phase":"PHASE1","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2024-01-09","conditions":"Unresectable Pancreatic Cancer","enrollment":58},{"nctId":"NCT06868693","phase":"","title":"Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer","status":"NOT_YET_RECRUITING","sponsor":"Azienda Unita Sanitaria Locale di Piacenza","startDate":"2026-01-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy","enrollment":240},{"nctId":"NCT05257993","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-03-30","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06538207","phase":"PHASE1","title":"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-01-13","conditions":"Metastatic Pancreatic Cancer","enrollment":46},{"nctId":"NCT02672917","phase":"PHASE1","title":"Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies","status":"TERMINATED","sponsor":"BioNTech Research & Development, Inc.","startDate":"2016-01","conditions":"Pancreatic Cancer","enrollment":118},{"nctId":"NCT06714604","phase":"PHASE3","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2023-10-18","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer","enrollment":432},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT03941093","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2019-05-10","conditions":"Pancreatic Cancer Non-resectable","enrollment":284},{"nctId":"NCT06378580","phase":"","title":"The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Luo Cong","startDate":"2022-07-01","conditions":"Pancreatic Cancer","enrollment":72},{"nctId":"NCT03714555","phase":"PHASE2","title":"Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2019-10-17","conditions":"Metastatic Pancreatic Cancer","enrollment":1},{"nctId":"NCT04324307","phase":"PHASE1, PHASE2","title":"Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2019-11-26","conditions":"Locally Advanced and Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT01726582","phase":"PHASE2","title":"Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-11","conditions":"Pancreatic Adenocarcinoma","enrollment":229},{"nctId":"NCT05679050","phase":"PHASE2","title":"Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-01","conditions":"Resectable Pancreatic Cancer","enrollment":30},{"nctId":"NCT02873598","phase":"PHASE1","title":"A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-11-17","conditions":"Pancreatic Cancer","enrollment":14},{"nctId":"NCT05557851","phase":"PHASE1","title":"Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas","status":"UNKNOWN","sponsor":"Minneamrita Therapeutics LLC","startDate":"2022-11-01","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":36},{"nctId":"NCT05524090","phase":"","title":"PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-07-01","conditions":"Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Non-resectable","enrollment":223},{"nctId":"NCT03003078","phase":"NA","title":"A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane","status":"COMPLETED","sponsor":"OncoSil Medical Limited","startDate":"2017-03-27","conditions":"Unresectable Locally Advanced Pancreatic Carcinoma","enrollment":50},{"nctId":"NCT01676259","phase":"PHASE2","title":"A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Silenseed Ltd","startDate":"2018-03-07","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer","enrollment":80},{"nctId":"NCT03536182","phase":"PHASE3","title":"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-05-29","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT04897854","phase":"PHASE3","title":"Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-04-22","conditions":"Metastatic Pancreas Cancer","enrollment":184},{"nctId":"NCT02717091","phase":"PHASE2","title":"Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Nagoya University","startDate":"2015-07","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":50},{"nctId":"NCT03600623","phase":"EARLY_PHASE1","title":"Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2017-09-25","conditions":"Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer","enrollment":25},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302},{"nctId":"NCT02548169","phase":"PHASE1","title":"Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2015-08","conditions":"Pancreatic Cancer","enrollment":7},{"nctId":"NCT03398291","phase":"PHASE3","title":"Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-07-01","conditions":"Pancreatic Cancer, Liver Metastases, Surgery","enrollment":300},{"nctId":"NCT03690323","phase":"NA","title":"Pancreatic Locally Advanced Irresectable Cancer Ablation","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-04-07","conditions":"Locally Advanced Pancreatic Cancer","enrollment":228},{"nctId":"NCT03633734","phase":"PHASE1, PHASE2","title":"Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-07-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect","enrollment":49},{"nctId":"NCT02243007","phase":"PHASE2","title":"Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2014-09","conditions":"Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma","enrollment":7},{"nctId":"NCT01488552","phase":"PHASE1, PHASE2","title":"Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Research Team","startDate":"2011-11","conditions":"Stage IV Pancreatic Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2088,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFIRINOX or gemcitabine-nab-paclitaxel","genericName":"FOLFIRINOX or gemcitabine-nab-paclitaxel","companyName":"Sahlgrenska University Hospital","companyId":"sahlgrenska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRINOX and gemcitabine-nab-paclitaxel are combination chemotherapy regimens that kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and microtubule disruption. Used for Metastatic pancreatic cancer (FOLFIRINOX), Metastatic pancreatic cancer (gemcitabine-nab-paclitaxel), Locally advanced pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}